Streetbeat News

Analyst Ratings

ACLX

HC Wainwright & Co. analyst Emily Bodnar reiterates a Buy rating on Arcellx (NASDAQ:ACLX) and maintains a $49 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 8:56 am

AGR

Keybanc analyst Sophie Karp has upgraded Avangrid (NYSE:AGR) from Underweight to Sector Weight.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 8:54 am

TM

Ark Investment Management expressed skepticism on Toyota Motor Corp's new electric vehicle (EV) strategy, stating that it does not appear poised for mass market success. Toyota's strategy involves the use of solid-state batteries, aiming for a range of 620 miles by 2027, which is a five-year delay from the original forecast.

Portfolio Pulse from Anan Ashraf

June 21, 2023 | 8:15 am

SHY

VGSH

Allianz chief economic adviser Mohamed El-Erian criticized Federal Reserve Chairman Jerome Powell's message to the market as 'confused and confusing.' El-Erian also stated that the Fed's inflation target is too low and should be higher. The iShares 1-3 Year Treasury Bond ETF (SHY) and Vanguard Short-Term Treasury Index Fund ETF (VGSH) experienced slight gains.

Portfolio Pulse from Bhavik Nair

June 21, 2023 | 4:47 am

F

TSLA

Jim Cramer believes investors should continue to own Tesla stock due to its growth potential but sees more value in Ford shares. He thinks Ford's stock could reach its high of $25 and prefers it over Tesla at current prices.

Portfolio Pulse from Bhavik Nair

June 21, 2023 | 2:28 am

ALT

BIIB

CYTK

MRNA

SGEN

Bank of America identified 12 disruptive healthcare technologies with potential to revolutionize the sector. Benzinga highlighted 5 biotech stocks related to these technologies: Altimmune Inc. (ALT), Moderna Inc (MRNA), Cytokinetics, Inc. (CYTK), Seagen Inc (SGEN), and Biogen Inc (BIIB).

Portfolio Pulse from Piero Cingari

June 20, 2023 | 9:14 pm

CNC

In the past 3 months, 10 analysts have published their opinions on Centene (NYSE:CNC) stock, with an average 12-month price target of $87.0, a 5.95% decrease from the previous average of $92.50. The ratings include 2 bullish, 7 somewhat bullish, and 1 indifferent.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 9:03 pm

AON

Analysts have provided indifferent ratings for Aon (NYSE:AON) within the last quarter, with an average price target of $327.71, slightly below the current price of $328.95. The average price target has increased by 1.67% from the previous average of $322.33.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 9:02 pm

RGNX

In the last quarter, Regenxbio (NASDAQ:RGNX) received 1 bullish, 3 somewhat bullish, and 1 indifferent rating from analysts. The company's average 12-month price target is $40.4, representing a 6.05% decrease from the previous average of $43.00.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 9:02 pm

ELV

Over the past 3 months, 8 analysts have published their opinion on Elevance Health (NYSE:ELV) stock, with 3 bullish and 5 somewhat bullish ratings. The average 12-month price target is $563.12, a 0.26% decrease from the previous average of $564.57.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 9:01 pm